What is Element Biosciences?
Element Biosciences is a pioneering life sciences technology company dedicated to the development of advanced genomic sequencing, multiomics, and biological analysis platforms. By integrating expertise in biology, engineering, software, and data science, the company provides researchers and healthcare organizations with the tools necessary to generate high-quality biological data. Its innovative sequencing technologies and flexible workflows are designed to accelerate breakthroughs in critical areas such as transcriptomics, proteomics, and spatial biology. Through its commitment to making high-quality data more accessible, Element Biosciences is actively shaping the future of precision medicine, drug development, and disease research, establishing itself as a vital infrastructure provider in the modern biotechnology ecosystem.
How much funding has Element Biosciences raised?
Element Biosciences has raised a total of $823M across 5 funding rounds:
Series A
$15M
Series B
$80M
Series C
$276M
Series D
$277M
Series E
$175M
Series A (2019): $15M with participation from Venrock and Foresite Capital
Series B (2020): $80M led by Venrock, JS Capital LLC, Foresite Capital, and Fidelity Management & Research Company
Series C (2021): $276M supported by Logos Capital, Janus Henderson Investors, and Meritech Capital Partners
Series D (2024): $277M featuring Fidelity, Wellington Management, Samsung Electronics, and Foresite Capital
Series E (2026): $175M backed by Samsung Electronics
Key Investors in Element Biosciences
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data.
Fidelity Management & Research Company
Fidelity Investments is a financial services company that provides a broad range of investment, wealth management, and advisory solutions for institutions and individual investors.
Samsung Electronics
Samsung Electronics is a global leader in technology and consumer electronics, driving innovation across semiconductors, medical devices, and digital health initiatives.
What's next for Element Biosciences?
With the successful closure of its latest financing round, Element Biosciences is well-positioned to accelerate its commercial expansion and deepen its R&D capabilities. The company is expected to leverage this capital to scale its manufacturing operations, enhance its integrated analysis solutions, and broaden its market reach within the global diagnostics and research sectors. As the demand for high-throughput, cost-effective genomic data continues to rise, Element Biosciences is strategically aligned to capture significant market share. Future initiatives will likely focus on strengthening its competitive moat through technological iteration and strategic partnerships, ensuring that its platforms remain the gold standard for scientific discovery and clinical application in an increasingly data-driven healthcare environment.
See full Element Biosciences company page
